Quarterly report [Sections 13 or 15(d)]

Condensed Consolidated Interim Statements of Loss and Comprehensive Loss (Unaudited)

v3.26.1
Condensed Consolidated Interim Statements of Loss and Comprehensive Loss (Unaudited) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Revenue $ 0 $ 0
Operating expenses:    
Research and development 3,621 2,364
General and administrative 3,561 3,097
Total operating expenses 7,182 5,461
Other income (expenses):    
Other (expense) income, net (19) 62
Interest expense, related party (433) (144)
Total other expenses (452) (82)
Net loss and comprehensive loss $ (7,634) $ (5,543)
Net loss per common share, basic $ (2.99) $ (2.61)
Net loss per common share, diluted $ (2.99) $ (2.61)
Weighted-average number of common shares outstanding, basic 2,552,429 2,126,287
Weighted-average number of common shares outstanding, diluted 2,552,429 2,126,287